June 12 (NBD) -- Tasly Pharmaceutical Group Co Ltd (600535.SH) has signed a license agreement with Japan's EA Pharma Co Ltd to introduce a kind of drug designed for the treatment of secondary hyperparathyroidism (SHPT) caused by impaired renal functions and hematodialysis, the Tianjin, China-based pharmaceutical company said Monday. 

According to data from IMS, one of the world's leading market research firms with a focus on the pharmaceutical and healthcare industry, worldwide sales of SHPT drugs available on the market reached 1.54 billion U.S. dollars in 2015.

Email: lansuying@nbd.com.cn